Adocia (Adocia) Institutional Ownership : 0.91% (As of May. 16, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Adocia Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adocia's institutional ownership is 0.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adocia's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adocia's Float Percentage Of Total Shares Outstanding is 0.00%.

Adocia Institutional Ownership Historical Data

The historical data trend for Adocia's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia Institutional Ownership Chart

Adocia Historical Data

The historical data trend for Adocia can be seen below:

	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30
Institutional Ownership	1.67	1.64	1.64	1.39	1.30	1.15	1.15	0.94	0.91	0.91

Adocia Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Adocia (Adocia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (OTCPK:ADOIF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ADOC:France A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.